Wuxi Apptec Co is an investment fund managing more than $38.6 billion ran by Edward Hu. There are currently 5 companies in Mr. Hu’s portfolio. The largest investments include Lyell Immunopharma Inc and Ambrx Biopharma, together worth $30.1 billion.
As of 30th January 2024, Wuxi Apptec Co’s top holding is 8,180,678 shares of Lyell Immunopharma Inc currently worth over $15.9 billion and making up 41.2% of the portfolio value.
In addition, the fund holds 1,000,000 shares of Ambrx Biopharma worth $14.2 billion, whose value fell approximately 0.1% in the past six months.
The third-largest holding is Adagene Inc worth $8.16 billion and the next is Purple Biotech worth $151 million, with 194,139 shares owned.
Currently, Wuxi Apptec Co's portfolio is worth at least $38.6 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Wuxi Apptec Co office and employees reside in Shanghai, China. According to the last 13-F report filed with the SEC, Edward Hu serves as the Director at Wuxi Apptec Co.
In the most recent 13F filing, Wuxi Apptec Co revealed that it had opened a new position in Lyell Immunopharma Inc and bought 8,180,678 shares worth $15.9 billion.
The two most similar investment funds to Wuxi Apptec Co are Park Avenue Institutional Advisers and Venator Capital Management. They manage $38.6 billion and $38.5 billion respectively.
Wuxi Apptec Co’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 37.7% of
the total portfolio value.
The fund focuses on investments in the United States as
40.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
40% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $256 million.
These positions were updated on February 6th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Lyell Immunopharma Inc |
Opened
8,180,678
|
$15,870,515,000 | 41.15% |
| Ambrx Biopharma Inc. |
Opened
1,000,000
|
$14,240,000,000 | 36.92% |
| Adagene Inc |
Opened
4,225,696
|
$8,161,509,000 | 21.16% |
| Purple Biotech Ltd. |
Opened
194,139
|
$151,428,000 | 0.39% |
| Castle Biosciences, Inc. |
Opened
6,636
|
$143,205,000 | 0.37% |
| No transactions found | |||
| Showing first 500 out of 5 holdings | |||